BIOMAT Database Logo BIOMAT Database Logo

Coreceptor utilization by human immunodeficiency virus type 1 is not a primary determinant of neutralization sensitivity. 1998

R A LaCasse, and K E Follis, and T Moudgil, and M Trahey, and J M Binley, and V Planelles, and S Zolla-Pazner, and J H Nunberg
Montana Biotechnology Center, The University of Montana, Missoula 59812, USA.

We have examined the relationship between coreceptor utilization and sensitivity to neutralization in a primary isolate of human immunodeficiency virus type 1 and its T-cell line-adapted (TCLA) derivative. We determined that adaptation of the primary-isolate (PI) virus 168P results in the loss of the unique capacity of PI viruses to utilize the CCR5 coreceptor and in the acquisition by the TCLA 168C virus of sensitivity to neutralization by V3-directed monoclonal antibodies (MAbs). In experiments wherein infection by 168P is directed via either the CCR5 or the CXCR4 pathway, we demonstrate that the virus, as well as pseudotyped virions bearing a molecularly cloned 168P envelope protein, remains refractory to neutralization by MAbs 257-D, 268-D, and 50.1 regardless of the coreceptor utilized. This study suggests that coreceptor utilization is not a primary determinant of differential neutralization sensitivity in PI and TCLA viruses.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D003001 Cloning, Molecular The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells. Molecular Cloning
D004279 DNA, Viral Deoxyribonucleic acid that makes up the genetic material of viruses. Viral DNA
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D001483 Base Sequence The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence. DNA Sequence,Nucleotide Sequence,RNA Sequence,DNA Sequences,Base Sequences,Nucleotide Sequences,RNA Sequences,Sequence, Base,Sequence, DNA,Sequence, Nucleotide,Sequence, RNA,Sequences, Base,Sequences, DNA,Sequences, Nucleotide,Sequences, RNA

Related Publications

R A LaCasse, and K E Follis, and T Moudgil, and M Trahey, and J M Binley, and V Planelles, and S Zolla-Pazner, and J H Nunberg
Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage.
March 1998, Journal of virology,
R A LaCasse, and K E Follis, and T Moudgil, and M Trahey, and J M Binley, and V Planelles, and S Zolla-Pazner, and J H Nunberg
Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage.
September 1998, Journal of virology,
R A LaCasse, and K E Follis, and T Moudgil, and M Trahey, and J M Binley, and V Planelles, and S Zolla-Pazner, and J H Nunberg
Antibody binding is a dominant determinant of the efficiency of human immunodeficiency virus type 1 neutralization.
November 2006, Journal of virology,
R A LaCasse, and K E Follis, and T Moudgil, and M Trahey, and J M Binley, and V Planelles, and S Zolla-Pazner, and J H Nunberg
Chemokine coreceptor usage by diverse primary isolates of human immunodeficiency virus type 1.
November 1998, Journal of virology,
R A LaCasse, and K E Follis, and T Moudgil, and M Trahey, and J M Binley, and V Planelles, and S Zolla-Pazner, and J H Nunberg
The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1.
February 1992, Proceedings of the National Academy of Sciences of the United States of America,
R A LaCasse, and K E Follis, and T Moudgil, and M Trahey, and J M Binley, and V Planelles, and S Zolla-Pazner, and J H Nunberg
Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage.
March 1998, Journal of virology,
R A LaCasse, and K E Follis, and T Moudgil, and M Trahey, and J M Binley, and V Planelles, and S Zolla-Pazner, and J H Nunberg
Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1.
December 1998, Journal of virology,
R A LaCasse, and K E Follis, and T Moudgil, and M Trahey, and J M Binley, and V Planelles, and S Zolla-Pazner, and J H Nunberg
Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated.
March 1994, Journal of virology,
R A LaCasse, and K E Follis, and T Moudgil, and M Trahey, and J M Binley, and V Planelles, and S Zolla-Pazner, and J H Nunberg
Macrophage tropism of human immunodeficiency virus type 1 and utilization of the CC-CKR5 coreceptor.
February 1997, Journal of virology,
R A LaCasse, and K E Follis, and T Moudgil, and M Trahey, and J M Binley, and V Planelles, and S Zolla-Pazner, and J H Nunberg
CXCR4 as a functional coreceptor for human immunodeficiency virus type 1 infection of primary macrophages.
October 1998, Journal of virology,
Copied contents to your clipboard!